reaxys_anonymous_20150921_214819_924[1]

Query

1. Query

boxylate (368 mg, 0.587 mmol, 74percent yield): 1H NMR (400 MHz, CDCl3): 8.73 (br m, IH), 8.62 (br s, IH), 8.14 (d, IH), 7.47 (dd, IH), 7.43-7.39 (m, IH), 7.20-7.12 (m, 2H), 4.38-4.21 (m, 2H), 4.16-4.01 (m, 2H), 4.01-3.88 (m, IH),

3.44-3.30 (m, IH), 2.98-2.83 (m, IH), 2.00-1.88 (m, IH), 1.71-1.50 (m, 6H), 1.44 (s, 9H); MS (EI) for C25H30FIN4O4: 597 (MH+).

Stage 1:With benzotriazol-1-ol, 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride in N,N-dimethyl-for-mamide, Time= 0.166667h, T= 20 °C

Stage 2:With triethylamine in N,N-dimethyl-formamide, Time= 0.333333h

Stage 3:With triethylamine in N,N-dimethyl-formamide, Time= 15h

Patent; EXELIXIS, INC.; WO2007/44515; (2007); (A1) English

View in Reaxys

residue was purified by column chromatography (silica gel, 60-80percent ethyl acetate in hexanes) to give 1,1- dime-thylethyl (25)-2- [ 1 -( { 3 -[(2-fluoro-4-iodophenyl)amino]pyridin-4-yl } carbonyl)-3 - hydroxyazetidin-3-yl]piperidine-l-carboxylate (368 mg, 0.587 mmol, 74percent yield): 1H NMR (400 MHz, CDCl3): 8.73 (br m, IH), 8.62 (br s, IH), 8.14 (d, IH), 7.47 (dd, IH), 7.43-7.39 (m, IH), 7.20-7.12 (m, 2H), 4.38-4.21 (m, 2H), 4.16-4.01 (m, 2H), 4.01-3.88 (m, IH), 3.44-3.30 (m, IH), 2.98-2.83 (m, IH), 2.00-1.88 (m, IH), 1.71- 1.50 (m, 6H), 1.44 (s, 9H); MS (EI) for C25H30FIN4O4: 597 (MH+).

Stage 1:With benzotriazol-1-ol, 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride in N,N-dimethyl-for-mamide, Time= 0.166667h, T= 20 °C

Stage 2:With triethylamine in N,N-dimethyl-formamide, Time= 6.33333h

Patent; EXELIXIS, INC.; WO2008/76415; (2008); (A1) English

View in Reaxys

(2S)-2-(l -{ [(phenylmethyl)oxy]carbonyl} -3-{ [(2i?)-3,3,3-trifluoro-2- (methyloxy)-2-phenylpropanoyl]oxy}azetidin-3-

yl)piperidine-l-carboxylate (105 mg, 19percent yield) and starting material (253 mg, 69percent recovery).[00335] The

starting material thus recovered was taken into dichloromethane (3 mL) followed by addition of DMAP (115 mg, 0.94

mmol) and (i?)-(-)-α-methoxy-α- trifluoromethylphenylacetyl chloride (105 μL, 0.56 mmol) and the mixture was allowed

to stir at room temperature over 12 hours. Proceeding as before afforded combined 1,1- dimethylethyl (2R)-2-(l-{[(phe-

nylmethyl)oxy]carbonyl}-3-{[(2i?)-3,3,3-trifluoro- 2-(methyloxy)-2-phenylpropanoyl]oxy}azetidin-3-yl)piperidine-l-car-

boxylate (46.6 mg, 8percent yield), the more polar 1,1 -dimethylethyl (25)-2-(l-{[(phenylmethyl)oxy]carbonyl}-3-{[(2i?)-

3,3,3-trifluoro-2-(methyloxy)-2-phenylpropanoyl]oxy}azetidin-3-yl)piperidine-l-carboxylate (228 mg, 41percent yield)

and starting material (100.8 mg, 27percent recovery).

With 4-(N,N-dimethlyamino)pyridine in dichloromethane, Time= 12h, T= 0 - 20 °C , Product distribution / selectivity

Patent; EXELIXIS, INC.; WO2007/44515; (2007); (A1) English

View in Reaxys

5 %, 19 %22:To a solution of 1 , 1 -dimethylethyl 2-(3-hydroxy- 1 - {[(phenylmethyl)oxy]carbonyl}azetidin-3-yl)piperidine-l-car-

boxylate (368 mg, 0.94 mmol), prepared using procedures similar to those described in Reference 5, in dichloromethane

(5 mL) was added DMAP (1 15 mg, 0.94 mmol) and the resulting solution was cooled to 00C. (i?)-(-)-α-Methoxy-α-

trifluoromethylphenylacetyl chloride (105 μL, 0.56 mmol) was added to the solution by syringe and the mixture

>was allowed to warm to room temperature then stirred an additional 12 hours. The solution was then partitioned with

saturated aqueous soldium bicarbonate and the organic phase dried over anhydrous magnesium sulfate then filtered

and concentrated to an oily residue. Silica gel flash chromatography using hexanes:ethyl acetate 3:1 as eluent afforded

the less polar 1,1-dimethylethyl (2R)-2-(\\- { [(phenylmethyl)oxy] carbonyl } -3 - { [(2i?)-3 ,3 ,3 -trifluoro-2-(methyloxy)-2-

phenylpropanoyl]oxy}azetidin-3-yl)piperidine-l-carboxylate (27.5 mg, 5percent yield), the more polar 1,1-dimethylethyl

(2S)-2-(l-{[(phenylmethyl)oxy]carbonyl}-3-{[(2/?)- 3,3,3-trifluoro-2-(methyloxy)-2-phenylpropanoyl]oxy}azetidin-3-yl)pi-

peridine-l- carboxylate (105 mg, 19percent yield) and starting material (253 mg, 69percent recovery).

With 4-(N,N-dimethlyamino)pyridine in dichloromethane, Time= 12h, T= 0 - 20 °C

Patent; EXELIXIS, INC.; WO2008/76415; (2008); (A1) English

View in Reaxys

5 - 22 %, 19 - 41 %22:To a solution of 1 , 1 -dimethylethyl 2-(3 -hydroxy- 1 - { [(phenylmethyl)oxy] carbonyl}azetidin-3-yl)piperidine-l-carboxylate (368 mg, 0.94 mmol), prepared using procedures similar to those described in Reference 5, in dichloro-methane (5 mL) was added DMAP (115 mg, 0.94 mmol) and the resulting solution was cooled to O0C. (R)-(-)-a- Me-thoxy-α-trifluoromethylphenylacetyl chloride (105 μL, 0.5

6 mmol) was added to the solution by syringe and the mixture was allowed to warm to room temperature then stirred an additional 12 hours. The solution was then partitioned with saturated aqueous soldium bicarbonate and the organic phase dried over anhydrous magnesium sulfate then filtered and concentrated to an oily residue. Silica gel flash chromatography using hexanes:ethyl acetate 3:1 as eluent afforded the less polar 1,1 -dimethyl ethyl (2/?)-2-(l-{[(phenylmethyl)oxy] carbonyl } -3 - { [(2R)-3 ,3 ,3 -trifluoro-2-(methyloxy)-2-phenylpropanoyl] oxy } azetidin-3- yl)piperidine-l-carboxylate (27.5 mg, 5percent yield), the more polar 1 , 1 -dimethy-lethyl (2S)-2-(l- {[(phenylmethyl)oxy]carbonyl}-3-{[(2i?)-3,3,3-trifluoro-2-(methyloxy)-2- phenylpropanoyl]oxy}azeti-

din-3-yl)piperidine-l-carboxylate (105 mg, 19percent yield) and starting material (253 mg, 69percent recovery).

[0610] The starting material thus recovered was taken into dichloromethane (3 mL) followed by addition of DMAP (115 mg, 0.94 mmol) and (7?)-(-)-α-methoxy-α- trifluoromethylphenylacetyl chloride (105 μL, 0.56 mmol) and the mixture was allowed to stir at room temperature over 12 hours. Proceeding as before afforded combined 1,1-dimethylethyl (2R)-2-(l -{ [(phenylmethyl)oxy]carbonyl}-3-{ [(27?)-3,3,3-trifluoro- 2-(methyloxy)-2-phenylpropano-

yl]oxy}azetidin-3-yl)piperidine-l-carboxylate (46.6 mg, 8percent yield), the more polar 1 , 1 -dimethylethyl (25r)-2-(l-{[(phenylmethyl)oxy]carbonyl}-3-{[(2i?)- 3,3,3-trifluoro-2-(methyloxy)-2-phenylpropanoyl]oxy}azetidin-3-yl)piperidine-l-carboxylate (228 mg, 41percent yield) and starting material (100.8 mg, 27percent recovery). [0611] The starting material thus recovered was taken into tetrahydrofuran- dichloromethane (1:1, 2 mL) followed by addition of DMAP (47 mg, 0.39 mmol) and (R)-(- )-α-methoxy-α-trifluoromethylphenylacetyl chloride (80 μL, 0.43 mmol) and the mixture was heated to 60 0C over 12 hours. Proceeding as before afforded combined less polar 1,1- dimethy lethy 1 (2λ)-2-( 1 - { [(phenyl-methyl)oxy] carbonyl } -3 - { [(2R)-3 ,3,3 -trifluoro-2- (methyloxy)-2-phenylpropanoyl]oxy}azetidin-3-yl)piperidine-l-car-boxylate (144 mg, 26 percent yield). The chiral ester derivatives thus obtained were again subject to silica gel flash chromatography using hexanes:ethyl acetate 3:1 as eluent to give the pure less polar 1,1- dimethylethyl (2i?)-2-( 1 -{ [(phenylmethyl)oxy] carbonyl } -3 - { [(2/?)-3 ,3 ,3 -trifluoro-2- (methyloxy)-2-phenylpropanoyl]oxy}azetidin-3-yl)piper-idine-l-carboxylate (122.8 mg, 22percent yield) and the more polar 1,1 -dimethylethyl (2S)-2-(l-{[(phenylmethyl)oxy]car-bonyl}-3- {[(2/?)-3,3,3-trifluoro-2-(methyloxy)-2-phenylpropanoyl]oxy}azetidin-3-yl)piperidine-l- carboxylate (177.6 mg, 32percent yield) both as colorless amorphous residues.

With 4-(N,N-dimethlyamino)pyridine in dichloromethane, Time= 12h, T= 0 - 60 °C

Patent; EXELIXIS, INC.; WO2008/124085; (2008); (A2) English View in Reaxys

Abigail R.; Kim, Angie I.; Koltun, Elena S.; Lougheed, Julie C.; Manalo, Jean-Claire L.; Martini, Jean-Francois; Nuss, John M.; Peto, Csaba J.; Tsang, Tsze H.; Yu, Peiwen; Johnston, Stuart; ACS Medicinal Chemistry Letters; vol. 3; nb. 5; (2012); p. 416 - 421

View in Reaxys